ClinicalTrials.Veeva

Menu

Immunological Characteristics of Patients With PID and IBD

S

Sheba Medical Center

Status

Unknown

Conditions

Primary Immune Deficiency Disorder
Inflammatory Bowel Diseases

Study type

Observational

Funder types

Other

Identifiers

NCT03148028
SHEBA-17-3824-DS-CTIL

Details and patient eligibility

About

The investigators wish to characterize alterations in the architecture and function of immune cells in patients with a primary immunodeficiency that also develop inflammatory bowel disease. In addition, The investigators' goal is to characterize the microbiome of these patients, in order to determine whether specific microbial alterations are related to inflammation.

Full description

The pathogenesis of inflammatory bowel diseases (IBD), like Crohn's disease and ulcerative colitis is complex and is thought to be related to genetic, environmental and microbial alterations that lead to a hyperactive/dysregulated immune system that mediates tissue damage. In rare cases, IBD can develop in patients with primary immunodeficiencies (PID) who develop severe, atypical or recurrent infections. The bowel disease in these patients can present after they develop infectious complications but also prior to that. The goal of the current study is to characterize immune function in patients with PID and IBD in order to identify alterations in pro-inflammatory and regulatory pathways.

The investigators will obtain blood samples from PID patients with IBD in order to perform deep immune profiling using various techniques such as flow cytometry, ELISA and others. Moreover, the investigators wish to characterize the microbiome of these patients. This multi-disciplinary approach will advance our understanding why specific patients with an immunodeficiency develop an IBD-like phenotype.

Enrollment

45 estimated patients

Sex

All

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age <18 years
  • diagnosis of an immunodeficiency
  • suspected or confirmed IBD

Exclusion criteria

  • none

Trial design

45 participants in 1 patient group

PID IBD patients
Description:
patients with an immunodeficiency and inflammatory bowel disease phenotype

Trial contacts and locations

2

Loading...

Central trial contact

Dror S Shouval, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems